centanafadine
Centanafadine (INN; former developmental code name EB-1020) is a serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI) that began its development with Euthymics Bioscience after they acquired DOV Pharmaceutical. It was developed as a treatment for attention-deficit hyperactivity disorder (ADHD) and inhibits the reuptake of norepinephrine, dopamine, and serotonin with an IC50 ratio of 1:6:14, respectively. In 2011, Euthymics Bioscience spun off its development of centanafadine to a new company called Neurovance. In March 2017, Otsuka Pharmaceutical acquired Neurovance and the rights to centanafadine. As of January 2018, Otsuka's pipeline indicates it is in Phase II and III clinical trials for a number of different applications to medical conditions. — Wikipedia
Clinical trial activity
22 trials · 4 clinical orgs · 0 marketing orgs
Earliest trial started Feb 1, 2013 (NCT01744808)
Timeline
Indications
Studied for
- Anxiety · Phase 3
- Anxiety Disorders · Phase 3
- Attention Deficit and Disruptive Behavior Disorders · Phase 3
- Attention Deficit Disorder with Hyperactivity · Phase 3
- Binge-Eating Disorder · Phase 2
- Drug Users · Phase 1
- Healthy Volunteers · Phase 1
- Major Depressive Disorder · Phase 2
- Phobia, Social · Phase 3
- Smoking Cessation · Phase 2
Mechanism of action
- Monoamine oxidase AINHIBITOR
MAOA inhibitor
- Monoamine transporterINHIBITOR
Monoamine transporter inhibitor
Inhibition ratio for norepinephrine, dopamine, serotonin; 1:6:14.
Chemistry & pharmacology
SMILES
c1ccc2cc([C@]34CNC[C@H]3C4)ccc2c1- Mol. weight
- 209.29 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- Yes
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3301621 ↗
- WikipediaCentanafadine ↗
- ChEMBLCHEMBL3301615 ↗
Also known as
- 1-(naphthalen-2-yl)-3-azabicyclo(3.1.0)hexane
- centanafadine
- centanafadine
- eb-1020
- eb-1020
- eb-1020
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07087327 | Phase 3 | Aug 31, 2025 | Otsuka |
| NCT07086313 | Phase 2/Phase 3 (Phase 3) | Aug 31, 2025 | Otsuka |
| NCT06926829 | Phase 3 | Jun 25, 2025 | Otsuka |
| NCT06931080 | Phase 2/Phase 3 (Phase 3) | Apr 30, 2025 | Otsuka |
| NCT06973577 | Phase 3 | Mar 26, 2025 | Otsuka |
| NCT05536414 | Phase 2 | Sep 12, 2022 | Otsuka |
| NCT05428033 | Phase 3 | Jul 11, 2022 | Otsuka |
| NCT05279313 | Phase 3 | Feb 24, 2022 | Otsuka |
| NCT05257265 | Phase 3 | Feb 2, 2022 | Otsuka |
| NCT05113953 | Phase 2 | Nov 8, 2021 | Otsuka |
| NCT05066724 | Phase 2 | Sep 13, 2021 | Otsuka, Rose Research Center, LLC |
| NCT04786730 | Phase 1 | Mar 9, 2021 | Otsuka |
| NCT04398225 | Phase 1 | Jun 30, 2020 | Otsuka |
| NCT04081363 | Phase 2 | Sep 30, 2019 | Otsuka |
| NCT03605836 | Phase 3 | Oct 31, 2018 | Otsuka |
| NCT03605849 | Phase 3 | Oct 31, 2018 | Otsuka |
| NCT03605680 | Phase 3 | Sep 30, 2018 | Otsuka |
| NCT02827513 | Phase 1 | Dec 1, 2015 | Neurovance, Inc. |
| NCT02547428 | Phase 2 | Aug 1, 2015 | Neurovance, Inc. |
| NCT02144415 | Phase 1 | May 1, 2014 | Neurovance, Inc. |
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Otsuka | For profit | 17 | 17 | 3 | 2018 |
| Neurovance, Inc. | For profit | 5 | 5 | 2 | 2013 |
| Florida Clinical Research Center, LLC | For profit | 1 | 0 | 1 | 2013 |
| Rose Research Center, LLC | For profit | 1 | 0 | 1 | 2021 |